launch in the middle of 2025. We have also made great progress on the clinical side, with the ENCORE and PAH studies nearing full enrollment. All of this has been accomplished while delivering yet another quarter of double-digit growth for ARIKAYCE in each of our three commercial regions. ...
Starting January 2024, Otsuka will cover the full cost of studies conducted by both Sumitomo Pharma Group and Otsuka, except for certain studies. KarXT (xanomeline–trospium) is an oral modulator targeting muscarinic receptors found in both the central nervous system (CNS) and various peripheral ...
Shanghai Henlius, a subsidiary, has successively granted various product licenses to Organon, Eurofarma, Getz Pharma and other companies, in order to cover incremental markets with the help of leading international partners. The Group continued to enhance its global operation capability, and made ...
review and meta-analyses of trials in healthy and clinical groups with implications for pharmacotherapy MJ Bakermans-Kranenburg1,2 and MH van IJzendoorn1,2 The popularity of oxytocin (OT) has grown exponentially during the past decade, and so has the number of OT trials...